LON:DEST Destiny Pharma (DEST) Share Price, News & Analysis → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free DEST Stock Alerts GBX 17 +1.38 (+8.83%) (As of 06/11/2024 ET) Add Compare Share Share Today's Range 16▼ 18.5150-Day Range 15.25▼ 2752-Week Range 13.20▼ 84Volume1.42 million shsAverage Volume461,591 shsMarket Capitalization£16.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades Get Destiny Pharma alerts: Email Address Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About Destiny Pharma Stock (LON:DEST)Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, dermal, oral and ocular infections. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; Sebela Pharmaceuticals; the University of Southampton; Aston University; the University of Sheffield; National Biofilms Innovation Centre; National Institute of Allergy and Infectious Diseases; Cystic Fibrosis Foundation; Cardiff University; and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.Read More DEST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DEST Stock News HeadlinesMay 28, 2024 | msn.comAstraZeneca Sets A New Pace in Cancer Care: From Latest Trials to Next-level TherapiesMay 28, 2024 | msn.comPro-Trump Investor Vivek Ramaswamy Says BuzzFeed Should Make ‘Large-Scale’ Layoffs and Hire Candace Owens, Tucker Carlson, Aaron RodgersMay 28, 2024 | msn.comTamil Nadu residents could soon avail government’s chopper services to fly across stateMay 28, 2024 | msn.comAlmac posts record-breaking sales after another year of growthMay 28, 2024 | finance.yahoo.comAntibiotic Resistance Markets Therapeutics, by Pathogen and Therapy Type to 2027: Search for Alternatives to Antibiotics Creates New Global GoldrushMay 16, 2024 | msn.comFull text of the Arab League summit's 'Bahrain declaration'May 7, 2024 | msn.comRedfall review: multiplayer sucks the life out of a promising vampire shooterMay 7, 2024 | msn.comCovid Vaccine – Is It India's Voldemort?April 26, 2024 | msn.com‘Covert City’ Review: The Cold War in MiamiApril 26, 2024 | msn.com‘The Last of Us,’ ‘Bluey,’ ‘Poker Face,’ ‘The Bear’ Among Peabody Award Nominations as More 2024 Contenders Are AnnouncedApril 25, 2024 | lse.co.ukTRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading wellApril 25, 2024 | msn.comMARKET REPORT: Meta sheds £130bn value after AI spending fearsApril 8, 2024 | usatoday.comCarol Ann Langford’s Legacy of Servant Leadership Informs Her Mission to Nurture Human InnovationApril 3, 2024 | msn.comMarcelo Weigandt opens up on Messi, Maradona, Inter Miami and why he wears No. 57March 28, 2024 | msn.com'Lefties losing it': Dr Jordan Peterson gives 'masterclass in lefty annihilation'March 20, 2024 | nytimes.comOprah, Ozempic and UsMarch 18, 2024 | bizjournals.comNKU College of Law, UK College of Medicine plan $150M riverfront facility in CovingtonMarch 16, 2024 | msn.comHolding up half the skyMarch 15, 2024 | msn.comIndia Mobilizes Aid Amid Haiti’s Gang Violence: 24-Hour Helpline and Evacuation Plans in MotionMarch 12, 2024 | msn.comRBI goes after ‘peer to peer’ transactions – Cred, NoBroker on radarMarch 11, 2024 | msn.comUR's New Vaccinology Programme Is a Step in the Right DirectionMarch 8, 2024 | abcnews.go.com'I believe in America': Fired-up Biden uses State of the Union to skewer GOP, his 'predecessor'March 8, 2024 | nytimes.comAn Instant Crush Over Mashed PotatoesMarch 6, 2024 | bizjournals.comBayer CEO on how he plans to fix a 'broken' companyFebruary 23, 2024 | dailymail.co.ukITV orders a drama depicting the contaminated blood scandal after Mr Bates Vs The Post Office sparked nationwide uproarSee More Headlines Receive DEST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Destiny Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/17/2020Today6/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:DEST CUSIPN/A CIKN/A Webwww.destinypharma.com Phone+44-1273-704440FaxN/AEmployees24Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-5,660,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-67.29% Return on Assets-44.90% Debt Debt-to-Equity RatioN/A Current Ratio9.89 Quick Ratio11.10 Sales & Book Value Annual Sales£135,028.00 Price / Sales120.00 Cash FlowGBX 6.32 per share Price / Cash Flow2.69 Book ValueGBX 10 per share Price / Book1.70Miscellaneous Outstanding Shares95,310,000Free FloatN/AMarket Cap£16.20 million OptionableNot Optionable Beta0.31 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. William Guy Love (Age 62)Founder, Chief Scientific Officer & Director Comp: $265kMr. Shaun Claydon ACA (Age 56)CFO, Company Secretary & Director Comp: $286kDr. Debra Barker M.D. (Age 62)MSc., Interim CMO & Senior Independent Director Comp: $41kMr. Christopher John Tovey BSc (Age 59)CEO & Director Key CompetitorsRedx PharmaLON:REDXe-therapeuticsLON:ETXArecor TherapeuticsLON:ARECTissue Regenix GroupLON:TRXSareumLON:SARView All Competitors DEST Stock Analysis - Frequently Asked Questions How have DEST shares performed in 2024? Destiny Pharma's stock was trading at GBX 70 at the beginning of 2024. Since then, DEST shares have decreased by 75.7% and is now trading at GBX 17. View the best growth stocks for 2024 here. How were Destiny Pharma's earnings last quarter? Destiny Pharma plc (LON:DEST) released its quarterly earnings data on Thursday, September, 17th. The company reported ($5.50) earnings per share (EPS) for the quarter. What other stocks do shareholders of Destiny Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Destiny Pharma investors own include Dynavax Technologies (DVAX), AFPO.L (AFPO), Aldeyra Therapeutics (ALDX), Ares Capital (ARCC), BioCryst Pharmaceuticals (BCRX), BioNTech (BNTX), Centamin (CEY), Countryside Partnerships (CSP), Enbridge (ENB) and EQTEC (EQT). How do I buy shares of Destiny Pharma? Shares of DEST stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:DEST) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Destiny Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Destiny Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.